Upstream Bio Q4 2025 Earnings Report

Upstream Bio EPS Results

• Actual EPS: -$0.79
• Consensus EPS: -$0.73
• Beat/Miss: Missed by -$0.06
• One Year Ago EPS: N/A

Upstream Bio Revenue Results

• Actual Revenue: $0.67 million
• Expected Revenue: $0.52 million
• Beat/Miss: Beat by +$146.00 thousand
• YoY Revenue Growth: N/A

Upstream Bio Announcement Details

• Quarter: Q4 2025
• Date: 3/26/2026
• Time: Before Market Opens
• Conference Call Date: N/A
• Conference Call Time: N/A

Upstream Bio (NASDAQ:UPB) is a clinical-stage biotechnology company focused on the development of next-generation prophylactic vaccines and immuno-oncology therapies. Leveraging a proprietary viral vector platform, the company aims to deliver optimized antigen payloads that stimulate robust and durable immune responses against both infectious diseases and cancer targets. Upstream Bio’s approach emphasizes safety, manufacturability and potential for rapid scale-up to address emerging public health challenges.

The company’s research and development pipeline includes multiple viral vector-based candidates in early clinical and preclinical stages. In the immuno-oncology sphere, Upstream Bio is exploring therapeutic vaccine constructs designed to activate tumor-specific T cells, while its infectious disease programs seek to induce protective immunity against viral pathogens. By integrating translational biomarkers and adaptive clinical trial designs, the company strives to accelerate candidate selection and optimize dosing regimens.

Upstream Bio operates research facilities in the United States and collaborates with academic and industry partners across several regions to advance its programs globally. The company’s leadership team comprises seasoned executives and scientists with deep expertise in virology, vaccine development and regulatory affairs. Upstream Bio is listed on the Nasdaq Global Market under the symbol UPB and continues to build strategic alliances aimed at expanding its pipeline and commercial capabilities.